Saturday, October 31, 2026

MP Materials plans 10,000-tonne magnet plant by 2028, challenging China's rare earth dominance

US-based MP Materials will scale rare earth magnet output from 1,000 to 10,000 tonnes annually by 2028 at its Fort Worth facility—equivalent to 15% of current global production. The expansion targets Western dependence on China, which controls 90% of rare earth refining capacity and supplies most magnets for electric vehicles and wind turbines worldwide.

ViaNews Editorial Team

February 22, 2026

Source Trace Score1 source document1 with a live linkVerifiability: Basic
MP Materials plans 10,000-tonne magnet plant by 2028, challenging China's rare earth dominance
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

MP Materials targets 10,000 metric tonnes of annual rare earth magnet output by 2028, a tenfold increase from current capacity at its Fort Worth, Texas facility. The expansion would produce roughly 15% of global magnet supply, directly challenging China's near-monopoly on rare earth processing and manufacturing.

China controls 90% of global rare earth refining capacity and dominates magnet production for electric vehicles, wind turbines, and defense systems worldwide. Western nations from the US to Europe and Australia have struggled to build alternative supply chains. MP Materials operates North America's only integrated rare earth site at Mountain Pass, California, extracting concentrate and processing oxides domestically before final magnet manufacturing.

The 10,000-tonne output could pressure neodymium-praseodymium oxide prices, which hit $160,000 per tonne in 2022 during supply concerns before falling to $50,000. Global automakers including Tesla, Volkswagen, and BYD face magnet procurement bottlenecks limiting EV production. European wind turbine makers Vestas and Siemens Gamesa similarly depend on Chinese rare earth supply.

Competitors include Australia's Lynas Rare Earths, which processes material in Malaysia, and Canada's Energy Fuels. Japan and South Korea have invested in rare earth stockpiles and recycling programs to reduce China exposure. The European Union designated rare earths as critical raw materials requiring domestic sourcing targets by 2030.

The 2028 timeline carries execution risk. Magnet manufacturing requires specialized sintering furnaces and coating systems that have delayed similar projects globally. MP Materials hasn't disclosed capital costs for the buildout, though comparable facilities run $400-600 million. US Inflation Reduction Act incentives offer tax credits for domestic EV supply chains, potentially securing forward contracts with automakers before production starts.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score1 source document1 with a live linkVerifiability: Basic
  1. [1]News articleYahoo Finance· January 13, 2026
    Will the US’ onshoring strategy remove China’s chokehold on REEs?

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com